04.24.15
Lilly
1Q Revenues: $4.6 billion (-1%)
1Q Earnings: $529.5 million (-27%)
Comments: Revenue in the U.S. increased 6% to $2.2 billion, driven by increased volumes for Cyramza (sales of $67.5 million), and the inclusion of revenue from Novartis Animal Health ($749.8 million, up 42%). Revenue outside the U.S. decreased 6% to $2.4 billion due to unfavorable impact of foreign exchange. Lingering effects of U.S. patent expirations for Cymbalta (-40% to $287 million) and Evista (-55% to $66.8 million) continue to negatively impact results. Zyprexa sales were down 22% to $219.5 million. Alimta sales were $573.0 million, down 9%. Cialis sales were up 1% to $538.3 million. Humalog sales were up 5% to 684.0 million.
1Q Revenues: $4.6 billion (-1%)
1Q Earnings: $529.5 million (-27%)
Comments: Revenue in the U.S. increased 6% to $2.2 billion, driven by increased volumes for Cyramza (sales of $67.5 million), and the inclusion of revenue from Novartis Animal Health ($749.8 million, up 42%). Revenue outside the U.S. decreased 6% to $2.4 billion due to unfavorable impact of foreign exchange. Lingering effects of U.S. patent expirations for Cymbalta (-40% to $287 million) and Evista (-55% to $66.8 million) continue to negatively impact results. Zyprexa sales were down 22% to $219.5 million. Alimta sales were $573.0 million, down 9%. Cialis sales were up 1% to $538.3 million. Humalog sales were up 5% to 684.0 million.